| Year |
Citation |
Score |
| 2023 |
Rai R, Dey DK, Benbrook DM, Chandra V. Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 161: 114422. PMID 36841028 DOI: 10.1016/j.biopha.2023.114422 |
0.389 |
|
| 2022 |
Rai R, Chandra V, Kennedy AL, Zuna RE, Benbrook DM. Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. Frontiers in Oncology. 12: 958536. PMID 36203464 DOI: 10.3389/fonc.2022.958536 |
0.353 |
|
| 2022 |
Benbrook DM. SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. Frontiers in Cell and Developmental Biology. 10: 848682. PMID 35281109 DOI: 10.3389/fcell.2022.848682 |
0.31 |
|
| 2021 |
Chandra V, Rai R, Benbrook DM. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. Cancers. 13. PMID 34066052 DOI: 10.3390/cancers13102322 |
0.386 |
|
| 2020 |
Rai R, Essel KG, Benbrook DM, Garland J, Zhao YD, Chandra V. Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer. Cancers. 12: 1273. PMID 32443471 DOI: 10.3390/Cancers12051273 |
0.48 |
|
| 2020 |
Kennedy AL, Rai R, Isingizwe ZR, Zhao YD, Lightfoot SA, Benbrook DM. Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. Cancers. 12. PMID 32429557 DOI: 10.3390/Cancers12051269 |
0.401 |
|
| 2020 |
Sharma A, Li M, Thavathiru E, Ibrahim M, Garcia-Contreras L, Benbrook DM, Woo S. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. The Aaps Journal. 22: 51. PMID 32086622 DOI: 10.1208/S12248-020-0421-Z |
0.351 |
|
| 2020 |
Isingizwe ZR, Benbrook DM. Abstract 2840: Development of a model of dihomo-gamma-linolenic acid interference with platelet promotion of ovarian cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-2840 |
0.336 |
|
| 2020 |
Vaughn K, Lausen J, Bruns M, Benbrook D, Hannafon B. A novel drug inhibits exosome content loading and secretion in ovarian cancer cells The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.04409 |
0.385 |
|
| 2020 |
Essel K, Benbrook D, Rai R, Chandra V. Sulforaphane as a Potential Therapeutic for Endometrial Cancer Gynecologic Oncology. 156: e30. DOI: 10.1016/J.Ygyno.2019.11.092 |
0.386 |
|
| 2019 |
Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel Ovarian Cancer Maintenance Therapy Targeted at Mortalin and Mutant p53. International Journal of Cancer. PMID 31845320 DOI: 10.1002/Ijc.32830 |
0.415 |
|
| 2019 |
Gnanasekaran KK, Pouland T, Bunce RA, Darrell Berlin K, Abuskhuna S, Bhandari D, Mashayekhi M, Zhou DH, Benbrook DM. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorganic & Medicinal Chemistry. 115244. PMID 31831296 DOI: 10.1016/J.Bmc.2019.115244 |
0.319 |
|
| 2019 |
Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. European Journal of Medicinal Chemistry. 170: 16-27. PMID 30878829 DOI: 10.1016/J.Ejmech.2019.03.010 |
0.388 |
|
| 2019 |
Ramraj SK, Benbrook DM. Abstract NT-104: SYNERGISTIC COMBINATION OF MORTALIN-TARGETING AND P53 REACTIVATOR DRUGS FOR OVARIAN CANCER Clinical Cancer Research. 25. DOI: 10.1158/1557-3265.Ovcasymp18-Nt-104 |
0.428 |
|
| 2019 |
Ramraj SK, Isingizwe ZR, Elayapillai SP, Bosley AL, Zhao YD, Benbrook DM. Abstract LB-244: Prevention of ovarian cancer tumor establishment with mortalin targeting and p53 reactivator drugs Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Lb-244 |
0.433 |
|
| 2019 |
Elayapillai SP, Ramraj SK, Benbrook DM, Gunderson CC. Abstract 4652: Repurposing mebendazole in combination with PRIMA1METfor ovarian cancer therapy Cancer Research. 79: 4652-4652. DOI: 10.1158/1538-7445.Am2019-4652 |
0.409 |
|
| 2019 |
Dockery LE, Ward JM, Vesely SK, Thavathiru E, Benbrook DM, Moore KN, Holman LL. Vitamin D, leptin, vitamin D receptor single nucleotide polymorphism and treatment-related morbidity in ovarian, primary peritoneal, and fallopian tube cancer Gynecologic Oncology. 154. DOI: 10.1016/J.Ygyno.2019.03.218 |
0.311 |
|
| 2018 |
Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and Anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Letters. PMID 29574275 DOI: 10.1016/J.Canlet.2018.03.027 |
0.383 |
|
| 2017 |
Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Investigational New Drugs. PMID 29273857 DOI: 10.1007/S10637-017-0550-0 |
0.741 |
|
| 2017 |
Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch A, Lang ML, Rao CV. Loss of natural killer T (NKT) cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. Immunology. PMID 28419443 DOI: 10.1111/Imm.12746 |
0.37 |
|
| 2017 |
Griffith J, Andrade D, Mehta M, Berry W, Benbrook DM, Aravindan N, Herman TS, Ramesh R, Munshi A. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncology Reports. 37: 2382-2390. PMID 28260023 DOI: 10.3892/Or.2017.5478 |
0.401 |
|
| 2017 |
Chandra V, Long A, Masamha CP, Benbrook DM. Abstract 3308: Mitophagy induction and interference with cancer-specific apoptosis in SHetA2-treated cells Cancer Research. 77: 3308-3308. DOI: 10.1158/1538-7445.Am2017-3308 |
0.786 |
|
| 2017 |
Ramraj SK, Pelikan R, Chandra V, Benbrook D. Abstract 3225: SHetA2 targets mortalin-p53 interaction in differential induction of apoptosis in ovarian cancer over normal cells Cancer Research. 77: 3225-3225. DOI: 10.1158/1538-7445.Am2017-3225 |
0.435 |
|
| 2017 |
Thavathiru E, Chandra V, Rai R, Benbrook D. Abstract 1798: Mortalin precursor as potential marker for chemoprevention with SHetA2 Cancer Research. 77: 1798-1798. DOI: 10.1158/1538-7445.Am2017-1798 |
0.383 |
|
| 2016 |
Walgama C, Al Mubarak ZH, Zhang B, Akinwale M, Pathiranage A, Deng J, Berlin KD, Benbrook DM, Krishnan S. Label-free Real-time Microarray Imaging of Cancer Protein-Protein Interactions and Their Inhibition by Small Molecules. Analytical Chemistry. PMID 26886845 DOI: 10.1021/Acs.Analchem.5B04234 |
0.308 |
|
| 2015 |
Okon IS, Ding Y, Coughlan KA, Wang Q, Song P, Benbrook DM, Zou MH. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. PMID 26701889 DOI: 10.18632/Oncotarget.6699 |
0.404 |
|
| 2015 |
Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic Options for Management of Endometrial Hyperplasia: An Update. Journal of Gynecologic Oncology. PMID 26463434 DOI: 10.3802/Jgo.2016.27.E8 |
0.315 |
|
| 2015 |
Ozpolat B, Benbrook DM. Targeting autophagy in cancer management - strategies and developments. Cancer Management and Research. 7: 291-9. PMID 26392787 DOI: 10.2147/Cmar.S34859 |
0.39 |
|
| 2015 |
DiSilvestro PA, Lightfoot SA, Benbrook DM. Ki-67 Expression in a Cervical Cancer Organotypic Model Correlates with Growth and EGF-R Expression. Journal of Lower Genital Tract Disease. 3: 111-5. PMID 25950557 DOI: 10.1046/J.1526-0976.1999.08095.X |
0.338 |
|
| 2015 |
Gnanasekaran KK, Benbrook DM, Nammalwar B, Thavathiru E, Bunce RA, Berlin KD. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. European Journal of Medicinal Chemistry. 96: 209-17. PMID 25880346 DOI: 10.1016/J.Ejmech.2015.03.070 |
0.381 |
|
| 2015 |
Slaughter KN, Okon II, McMeekin S, Benbrook D, Scott B, Moore K. Expression Profiles of LKB1/AMPK in Endometrial Cancer Specimens as a Potential Biomarker for Targeted Metabolic Drug Therapy Brachytherapy. 14: 100-101. DOI: 10.1016/J.Ygyno.2014.03.322 |
0.316 |
|
| 2014 |
Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecologic Oncology. 135: 38-43. PMID 25019571 DOI: 10.1016/J.Ygyno.2014.07.083 |
0.375 |
|
| 2014 |
Benbrook DM, Chambon P, Rochette-Egly C, Asson-Batres MA. History of retinoic acid receptors. Sub-Cellular Biochemistry. 70: 1-20. PMID 24962878 DOI: 10.1007/978-94-017-9050-5_1 |
0.333 |
|
| 2014 |
Bishop EA, Lightfoot S, Thavathiru E, Benbrook DM. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Investigation. 32: 63-70. PMID 24499106 DOI: 10.3109/07357907.2013.877479 |
0.331 |
|
| 2014 |
Benbrook DM, Nammalwar B, Long A, Matsumoto H, Singh A, Bunce RA, Berlin KD. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. Investigational New Drugs. 32: 412-23. PMID 24254390 DOI: 10.1007/S10637-013-0041-X |
0.398 |
|
| 2014 |
Slaughter K, Thai T, Penaroza S, Benbrook D, Thavathiro E, Ding K, McMeekin D, Moore K. Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer (EOC) Gynecologic Oncology. 133: 171. DOI: 10.1016/J.Ygyno.2014.03.451 |
0.342 |
|
| 2013 |
Benbrook DM, Guruswamy S, Wang Y, Sun Z, Mohammed A, Zhang Y, Li Q, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prevention Research (Philadelphia, Pa.). 6: 908-16. PMID 23852423 DOI: 10.1158/1940-6207.Capr-13-0171 |
0.638 |
|
| 2013 |
Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecologic Oncology. 130: 377-82. PMID 23632208 DOI: 10.1016/J.Ygyno.2013.04.054 |
0.332 |
|
| 2013 |
Naylor MF, Thompson DM, Lightfoot S, Benbrook DM. Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer Journal of Cancer Therapy. 4: 7-19. DOI: 10.4236/Jct.2013.46A1002 |
0.494 |
|
| 2013 |
Lightfoot S, Zhao D, Thavathiru E, Benbrook DM. Abstract 3703: SHetA2 decreases mitoses and growth, and alters pathology of MNU-induced rat mammary tumors. Cancer Research. 73: 3703-3703. DOI: 10.1158/1538-7445.Am2013-3703 |
0.329 |
|
| 2012 |
Doppalapudi RS, Riccio ES, Davis Z, Menda S, Wang A, Du N, Green C, Kopelovich L, Rao CV, Benbrook DM, Kapetanovic IM. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutation Research. 746: 78-88. PMID 22498038 DOI: 10.1016/J.Mrgentox.2012.03.009 |
0.309 |
|
| 2012 |
Ramachandran I, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook DM, Zuna R, Lightfoot S, Reis A, Anant S, Queimado L. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo Oncogene. 31: 2725-2737. PMID 22002305 DOI: 10.1038/Onc.2011.455 |
0.46 |
|
| 2012 |
Benbrook D, Bishop E, Nugent E, Lightfoot S, Elangovan T, Long A, Zhao D. Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-P56 |
0.367 |
|
| 2011 |
Jiang H, Taggart JE, Zhang X, Benbrook DM, Lind SE, Ding WQ. Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). Cancer Letters. 312: 11-7. PMID 21899946 DOI: 10.1016/J.Canlet.2011.06.032 |
0.396 |
|
| 2011 |
Benbrook DM, Masamha CP. The pro-survival function of Akt kinase can be overridden or altered to contribute to induction of apoptosis. Current Cancer Drug Targets. 11: 586-99. PMID 21486222 DOI: 10.2174/156800911795655994 |
0.758 |
|
| 2011 |
Ramachandran I, Reis AMC, Anant S, Queimado L, Thavathiru E, Ramalingam S, Natarajan G, Mills WK, Benbrook D, Zuna R, Lightfoot S. Abstract C21: Wnt inhibitory factor 1 is silenced by promoter hypermethylation in cervical cancer and its restoration suppresses tumor growth Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-C21 |
0.437 |
|
| 2011 |
Bishop EA, Lightfoot SA, Benbrook DM. Abstract 1341: Insulin directly induces endometrial cell proliferation and carcinogenesis Cancer Research. 71: 1341-1341. DOI: 10.1158/1538-7445.Am2011-1341 |
0.326 |
|
| 2011 |
Bishop E, Lightfoot S, Benbrook D. Insulin promotes proliferation and carcinogenesis of normal endometrial cells Gynecologic Oncology. 120: S50. DOI: 10.1016/J.Ygyno.2010.12.122 |
0.304 |
|
| 2010 |
Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic Oncology. 119: 444-50. PMID 20846715 DOI: 10.1016/J.Ygyno.2010.08.002 |
0.334 |
|
| 2010 |
Zheng J, Lou JR, Zhang XX, Benbrook DM, Hanigan MH, Lind SE, Ding WQ. N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Letters. 298: 186-94. PMID 20667650 DOI: 10.1016/J.Canlet.2010.07.003 |
0.384 |
|
| 2010 |
Chengedza S, Benbrook DM. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anti-Cancer Drugs. 21: 297-305. PMID 20032777 DOI: 10.1097/Cad.0B013E3283350E43 |
0.764 |
|
| 2010 |
Guruswamy S, Benbrook D, Zhang Y, Qian L, Mohammed A, Rao CV. Abstract A140: Chemoprevention of familial adenomatous polyposis by a flexible‐heteroarotinoid (Flex‐Het), SHetA2, in APCMin mice Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-09-A140 |
0.63 |
|
| 2010 |
Zheng J, Lou JR, Benbrook DM, Hanigan MH, Lind SE, Ding W. Abstract 4382: N-acetylcysteine interacts with Cu++ to induce cancer cell death through the generation of hydrogen peroxide Cancer Research. 70: 4382-4382. DOI: 10.1158/1538-7445.Am10-4382 |
0.389 |
|
| 2010 |
Moxley KM, Chengedza S, Benbrook DM. Erratum to “Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents” [Gynecol. Oncol. 115 (2009) 438–442] Gynecologic Oncology. 117: 510. DOI: 10.1016/J.Ygyno.2010.02.026 |
0.755 |
|
| 2009 |
Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecologic Oncology. 115: 438-42. PMID 19804900 DOI: 10.1016/J.Ygyno.2009.09.007 |
0.787 |
|
| 2009 |
Palwai NR, Zang XP, Harrison RG, Benbrook D, Pento JT. Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology. 84: 271-5. PMID 19797936 DOI: 10.1159/000242997 |
0.414 |
|
| 2009 |
Masamha CP, Benbrook DM. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Research. 69: 6565-72. PMID 19638577 DOI: 10.1158/0008-5472.Can-09-0913 |
0.761 |
|
| 2009 |
Tuller ER, Beavers CT, Lou JR, Ihnat MA, Benbrook DM, Ding WQ. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. Molecular Pharmacology. 76: 588-95. PMID 19528198 DOI: 10.1124/Mol.109.057430 |
0.422 |
|
| 2009 |
Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochemical Pharmacology. 77: 1480-6. PMID 19426685 DOI: 10.1016/J.Bcp.2009.02.002 |
0.442 |
|
| 2009 |
Liu T, Masamha CP, Chengedza S, Berlin KD, Lightfoot S, He F, Benbrook DM. Development of flexible-heteroarotinoids for kidney cancer. Molecular Cancer Therapeutics. 8: 1227-38. PMID 19417155 DOI: 10.1158/1535-7163.Mct-08-1069 |
0.778 |
|
| 2009 |
Myers T, Chengedza S, Lightfoot S, Pan Y, Dedmond D, Cole L, Tang Y, Benbrook DM. Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. Investigational New Drugs. 27: 304-18. PMID 18802666 DOI: 10.1007/S10637-008-9175-7 |
0.79 |
|
| 2008 |
Benbrook DM, Lightfoot S, Ranger-Moore J, Liu T, Chengedza S, Berry WL, Dozmorov I. Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. Gene Regulation and Systems Biology. 2: 21-42. PMID 19784388 DOI: 10.4137/Grsb.S344 |
0.763 |
|
| 2008 |
Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, Khuri FR, Sun SY. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Molecular Cancer Therapeutics. 7: 3556-65. PMID 19001438 DOI: 10.1158/1535-7163.Mct-08-0648 |
0.432 |
|
| 2008 |
Liu Z, Zhang Y, Hua YF, Covey JM, Benbrook DM, Chan KK. Metabolism of a sulfur-containing heteroarotionoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry : Rcm. 22: 3371-81. PMID 18837006 DOI: 10.1002/Rcm.3744 |
0.301 |
|
| 2008 |
Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Research. 68: 5335-44. PMID 18593935 DOI: 10.1158/0008-5472.Can-07-6209 |
0.463 |
|
| 2008 |
Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Research. 68: 1636-46. PMID 18339842 DOI: 10.1158/0008-5472.Can-07-2345 |
0.317 |
|
| 2008 |
Masamha C, Benbrook D. Abstract A13: Chemoprevention agent SHetA2 induces G1 arrest through modulation of a biological system driven by Cyclin D1 Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-A13 |
0.765 |
|
| 2007 |
Le TC, Berlin KD, Benson SD, Eastman MA, Bell-Eunice G, Nelson AC, Benbrook DM. Heteroarotinoids with anti-cancer activity against ovarian cancer cells. The Open Medicinal Chemistry Journal. 1: 11-23. PMID 19662136 DOI: 10.2174/1874104500701010011 |
0.386 |
|
| 2007 |
Liu T, Hannafon B, Gill L, Kelly W, Benbrook D. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Molecular Cancer Therapeutics. 6: 1814-22. PMID 17575110 DOI: 10.1158/1535-7163.Mct-06-0279 |
0.43 |
|
| 2007 |
McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology. 105: 508-16. PMID 17306350 DOI: 10.1016/J.Ygyno.2007.01.019 |
0.347 |
|
| 2006 |
Hyde J, Benbrook DM. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug. American Journal of Pharmacology and Toxicology. 1: 83-86. PMID 19890461 DOI: 10.3844/Ajptsp.2006.83.86 |
0.451 |
|
| 2006 |
Matsuzaki S, Hayes JM, Benbrook DM, Jankowiak R. Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. The Journal of Physical Chemistry. B. 110: 16124-30. PMID 16898770 DOI: 10.1021/Jp060114I |
0.362 |
|
| 2006 |
Chiu PM, Feng HC, Benbrook DM, Ngan HY, Khoo US, Xue WC, Tsao SW, Chan KW, Cheung AN. Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. Journal of Clinical Pathology. 59: 845-50. PMID 16461808 DOI: 10.1136/Jcp.2005.025833 |
0.339 |
|
| 2006 |
Guruswamy S, Benbrook DM. Retinoids Chemosensitize Ovarian Cancer Cell Lines to Cisplatin Independent of Nuclear Receptors and p53 American Journal of Pharmacology and Toxicology. 1: 87-93. DOI: 10.3844/Ajptsp.2006.87.93 |
0.7 |
|
| 2006 |
Lu S, Benbrook DM. Role of AP-1 Antagonism in Growth Inhibition of Cervical Cancer Cell Lines by Retinoids American Journal of Pharmacology and Toxicology. 1: 40-47. DOI: 10.3844/Ajptsp.2006.40.47 |
0.647 |
|
| 2006 |
Benbrook DM. Organotypic cultures represent tumor microenvironment for drug testing Drug Discovery Today: Disease Models. 3: 143-148. DOI: 10.1016/J.Ddmod.2006.05.005 |
0.318 |
|
| 2005 |
Benbrook DM, Kamelle SA, Guruswamy SB, Lightfoot SA, Rutledge TL, Gould NS, Hannafon BN, Dunn ST, Berlin KD. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Investigational New Drugs. 23: 417-28. PMID 16133793 DOI: 10.1007/S10637-005-2901-5 |
0.696 |
|
| 2005 |
Tillmanns TD, Kamelle SA, Guruswamy S, Gould NS, Rutledge TL, Benbrook DM. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecologic Oncology. 97: 142-50. PMID 15790450 DOI: 10.1016/J.Ygyno.2004.12.034 |
0.628 |
|
| 2005 |
Subramanian S, Smith CM, Tabatabai A, Bryan CD, Buettner B, Hale S, Wakefield CA, Benbrook DM, Berlin KD. Synthesis of novel heteroarotinoids with receptor activation capabilities and tgase activity. Single crystal analysis of (E)-4-[(2,3-dihydro-2,2,4,4,- tetramethyl-2H-1-benzo-[b]thiopyran-6-Yl)-1-propenyl]-2-methylbenzoic acid Phosphorus, Sulfur and Silicon and the Related Elements. 180: 67-77. DOI: 10.1080/104265090507678 |
0.301 |
|
| 2004 |
Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. Journal of Medicinal Chemistry. 47: 999-1007. PMID 14761202 DOI: 10.1021/Jm030346V |
0.693 |
|
| 2003 |
Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. Cancer Research. 63: 3826-32. PMID 12839980 |
0.362 |
|
| 2003 |
Benbrook DM. Nature Reviews Cancer Jama: the Journal of the American Medical Association. 289: 1049-1050. DOI: 10.1001/Jama.289.8.1049 |
0.344 |
|
| 2002 |
Benbrook DM. Refining retinoids with heteroatoms Mini Reviews in Medicinal Chemistry. 2: 277-283. PMID 12370069 DOI: 10.2174/1389557023406160 |
0.328 |
|
| 2002 |
Scribner DR, Benbrook DM. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecologic Oncology. 85: 223-5. PMID 11925151 DOI: 10.1006/Gyno.2002.6590 |
0.426 |
|
| 2001 |
Simoni D, Roberti M, Invidiata FP, Rondanin R, Baruchello R, Malagutti C, Mazzali A, Rossi M, Grimaudo S, Capone F, Dusonchet L, Meli M, Raimondi MV, Landino M, D'Alessandro N, ... ... Benbrook DM, et al. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells Journal of Medicinal Chemistry. 44: 2308-2318. PMID 11428925 DOI: 10.1021/Jm0010320 |
0.616 |
|
| 2001 |
Guruswamy S, Lightfoot S, Gold MA, Hassan R, Berlin KD, Ivey RT, Benbrook DM. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. Journal of the National Cancer Institute. 93: 516-25. PMID 11287445 DOI: 10.1093/Jnci/93.7.516 |
0.67 |
|
| 2000 |
Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, Ivey RT, Zacheis D, Brown CW, Nelson EC, Birckbichler PJ, Benbrook DM. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids Journal of Medicinal Chemistry. 43: 303. PMID 10650065 |
0.478 |
|
| 1999 |
Hurst RE, Waliszewski P, Waliszewska M, Bonner RB, Benbrook DM, Dar A, Hemstreet GP. Complexity, retinoid-responsive gene networks, and bladder carcinogenesis Advances in Experimental Medicine and Biology. 462: 449-467. PMID 10599447 DOI: 10.1007/978-1-4615-4737-2_35 |
0.377 |
|
| 1999 |
Zacheis D, Dhar A, Lu S, Madler MM, Klucik J, Brown CW, Liu S, Clement F, Subramanian S, Weerasekare GM, Berlin KD, Gold MA, Houck JR, Fountain KR, Benbrook DM. Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. Journal of Medicinal Chemistry. 42: 4434-45. PMID 10543887 DOI: 10.1021/Jm990292I |
0.633 |
|
| 1999 |
Dhar A, Liu S, Klucik J, Berlin KD, Madler MM, Lu S, Ivey RT, Zacheis D, Brown CW, Nelson EC, Birckbichler PJ, Benbrook DM. Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. Journal of Medicinal Chemistry. 42: 3602-14. PMID 10479291 DOI: 10.1021/Jm9900974 |
0.634 |
|
| 1999 |
Salsman S, Lu S, Benbrook DM. The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. Gynecologic Oncology. 73: 253-6. PMID 10329043 DOI: 10.1006/Gyno.1999.5352 |
0.603 |
|
| 1999 |
Waliszewski P, Waliszewska M, Gordon N, Hurst RE, Benbrook DM, Dhar A, Hemstreet GP. Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells Molecular and Cellular Endocrinology. 148: 55-65. PMID 10221771 DOI: 10.1016/S0303-7207(98)00235-4 |
0.36 |
|
| 1997 |
Benbrook DM, Madler MM, Spruce LW, Birckbichler PJ, Nelson EC, Subramanian S, Weerasekare GM, Gale JB, Patterson MK, Wang B, Wang W, Lu S, Rowland TC, DiSivestro P, Lindamood C, et al. Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. Journal of Medicinal Chemistry. 40: 3567-83. PMID 9357524 DOI: 10.1021/Jm970196M |
0.623 |
|
| 1997 |
Benbrook DM, Lu S, Flanagan C, Shen-Gunther J, Angros LH, Lightfoot SA. Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. Gynecologic Oncology. 66: 114-21. PMID 9234931 DOI: 10.1006/Gyno.1997.4736 |
0.63 |
|
| 1995 |
Benbrook DM, Rogers RS, Medlin MA, Dunn ST. Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. Tissue & Cell. 27: 269-74. PMID 7645007 DOI: 10.1016/S0040-8166(95)80047-6 |
0.344 |
|
| 1994 |
Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Molecular and Cellular Biology. 14: 7025-35. PMID 7935418 DOI: 10.1128/Mcb.14.10.7025 |
0.301 |
|
| 1988 |
Benbrook D, Lernhardt E, Pfahl M. A new retinoic acid receptor identified from a hepatocellular carcinoma. Nature. 333: 669-72. PMID 2836738 DOI: 10.1038/333669A0 |
0.321 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2008 |
Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuma RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc (Cancer Research (2008) 68, (1636-1646)) Cancer Research. 68: 3076. DOI: 10.1158/0008-5472.Can-68-8-Cor2 |
0.3 |
|
| 2017 |
Mahjabeen S, Hatipoglu MK, Chandra V, Benbrook DM, Garcia-Contreras L. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. Journal of Pharmaceutical Sciences. PMID 28989018 DOI: 10.1016/J.Xphs.2017.09.018 |
0.299 |
|
| 2006 |
Zhang Y, Hua Y, Benbrook DM, Covey JM, Dai G, Liu Z, Chan KK. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. Cancer Chemotherapy and Pharmacology. 58: 561-9. PMID 16534614 DOI: 10.1007/S00280-006-0211-Z |
0.298 |
|
| 2004 |
Brown CW, Liu S, Klucik J, Berlin KD, Brennan PJ, Kaur D, Benbrook DM. Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. Journal of Medicinal Chemistry. 47: 1008-17. PMID 14761203 DOI: 10.1021/Jm0303453 |
0.296 |
|
| 2011 |
Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecologic Oncology. 121: 455-61. PMID 21414654 DOI: 10.1016/J.Ygyno.2011.02.013 |
0.295 |
|
| 2018 |
Watts FM, Pouland T, Bunce RA, Berlin KD, Benbrook DM, Mashayekhi M, Bhandari D, Zhou D. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. European Journal of Medicinal Chemistry. 158: 720-732. PMID 30245396 DOI: 10.1016/J.Ejmech.2018.09.036 |
0.294 |
|
| 2002 |
Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3520-6. PMID 12429643 |
0.293 |
|
| 2002 |
Benbrook DM. An ELISA method for detection of human antibodies to an immunotoxin. Journal of Pharmacological and Toxicological Methods. 47: 169-75. PMID 12628308 DOI: 10.1016/S1056-8719(02)00232-0 |
0.292 |
|
| 2013 |
Kabirov KK, Kapetanovic IM, Benbrook DM, Dinger N, Mankovskaya I, Zakharov A, Detrisac C, Pereira M, MartÃn-Jiménez T, Onua E, Banerjee A, van Breemen RB, Nikolić D, Chen L, Lyubimov AV. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug and Chemical Toxicology. 36: 284-95. PMID 22947079 DOI: 10.3109/01480545.2012.710632 |
0.292 |
|
| 1987 |
Benbrook D, Pfahl M. A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library. Science (New York, N.Y.). 238: 788-91. PMID 3672126 DOI: 10.1126/Science.3672126 |
0.29 |
|
| 2014 |
Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, Nelson T, McMeekin DS, Moore KN. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecologic Oncology. 133: 11-5. PMID 24680585 DOI: 10.1016/J.Ygyno.2014.01.031 |
0.289 |
|
| 2012 |
Benbrook DM, Long A. Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. Experimental Oncology. 34: 286-97. PMID 23070014 |
0.289 |
|
| 2020 |
Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, Isingizwe ZR, Kennedy AL, Zhao YD, Lightfoot S, Hunsucker LA, Gunderson CC. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecologic Oncology. PMID 33131904 DOI: 10.1016/j.ygyno.2020.10.010 |
0.28 |
|
| 2017 |
Razaq W, Tanaka T, Carlson B, Wenger M, Friedman J, Benbrook D, Craft M. Abstract P4-20-09: Diagnosing cognitive impairment (“chemo brain”) in breast cancer survivors Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-20-09 |
0.28 |
|
| 1999 |
Liu S, Berlin KD, Simms-Kelley MD, Nelson EC, Benbrook DM. Optimization and synthesis of (E)-4-[2-(3,4-dihydro-4,4-dimethyl-2H-1-benzopyran-6-y1)-1-propenyl]benzoic acid-11-[14C] Journal of Labelled Compounds and Radiopharmaceuticals. 42: 789-796. DOI: 10.1002/(Sici)1099-1344(199908)42:8<789::Aid-Jlcr239>3.0.Co;2-# |
0.28 |
|
| 2018 |
Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. Plos One. 13: e0194046. PMID 29634717 DOI: 10.1371/Journal.Pone.0194046 |
0.28 |
|
| 2021 |
Rai R, Kennedy AL, Isingizwe ZR, Javadian P, Benbrook DM. Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. Cells. 10. PMID 34831218 DOI: 10.3390/cells10112996 |
0.277 |
|
| 2023 |
Rai R, Lightfoot S, Benbrook DM. Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts. Gynecologic Oncology. 180: 44-54. PMID 38052108 DOI: 10.1016/j.ygyno.2023.11.013 |
0.277 |
|
| 2018 |
Mahjabeen S, Hatipoglu MK, Benbrook DM, Kosanke SD, Garcia-Contreras D, Garcia-Contreras L. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V. 130: 272-280. PMID 30064701 DOI: 10.1016/J.Ejpb.2018.07.004 |
0.274 |
|
| 2006 |
Benbrook DM. Promise and problems of translational research. Gynecologic Oncology. 103: S14-7. PMID 17027066 DOI: 10.1016/J.Ygyno.2006.08.019 |
0.273 |
|
| 2018 |
Ramraj SK, Smith KM, Janakiram NB, Toal C, Raman A, Benbrook DM. Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue & Cell. 52: 57-64. PMID 29857829 DOI: 10.1016/J.Tice.2018.04.001 |
0.271 |
|
| 1998 |
Benbrook DM, Subramanian S, Gale JB, Liu S, Brown CW, Boehm MF, Berlin KD. Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. Journal of Medicinal Chemistry. 41: 3753-7. PMID 9733501 DOI: 10.1021/Jm980308P |
0.271 |
|
| 2017 |
Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA, Spirtos NM, Byron J, Thaker PH, Lele S, et al. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28285845 DOI: 10.1016/J.Ygyno.2017.02.040 |
0.268 |
|
| 1997 |
Johnson GA, Mannel R, Khalifa M, Walker JL, Wren M, Min KW, Benbrook DM. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival Gynecologic Oncology. 65: 425-429. PMID 9190969 DOI: 10.1006/Gyno.1997.4660 |
0.263 |
|
| 1994 |
Benbrook DM, Jones NC. Different binding specificities and transactivation of variant CRE's by CREB complexes Nucleic Acids Research. 22: 1463-1469. PMID 8190638 DOI: 10.1093/Nar/22.8.1463 |
0.26 |
|
| 2012 |
Zakharov AD, Kabirov KK, Nikolić D, Chen L, Mankovskaya I, Breemen RBv, Benbrook DM, Kapetanovic IM, Lyubimov AV. Abstract 4781: Analysis of a new chemopreventative agent SHetA2 and its metabolites in Beagle dog liver and plasma Cancer Research. 72: 4781-4781. DOI: 10.1158/1538-7445.Am2012-4781 |
0.259 |
|
| 2018 |
Mahjabeen S, Hatipoglu MK, Benbrook DM, Garcia-Contreras L. Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Sheta2 After Vaginal Administration To Mice. Journal of Pharmaceutical Sciences. PMID 30196041 DOI: 10.1016/J.Xphs.2018.08.024 |
0.258 |
|
| 2003 |
Mic FA, Molotkov A, Benbrook DM, Duester G. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proceedings of the National Academy of Sciences of the United States of America. 100: 7135-40. PMID 12782789 DOI: 10.1073/Pnas.1231422100 |
0.257 |
|
| 2016 |
Gunderson CC, Ding K, Dvorak J, Moore KN, McMeekin DS, Benbrook DM. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecologic Oncology. PMID 27423378 DOI: 10.1016/J.Ygyno.2016.07.103 |
0.252 |
|
| 2019 |
Csiszar A, Balasubramanian P, Tarantini S, Yabluchanskiy A, Zhang XA, Springo Z, Benbrook D, Sonntag WE, Ungvari Z. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. PMID 31037472 DOI: 10.1007/s11357-019-00064-4 |
0.252 |
|
| 2022 |
Javadian P, Xu C, Sjoelund V, Borden LE, Garland J, Benbrook DM. Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. International Journal of Molecular Sciences. 23. PMID 35887124 DOI: 10.3390/ijms23147779 |
0.246 |
|
| 2021 |
Javadian P, Washington C, Mukasa S, Benbrook DM. Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity. Cancers. 13. PMID 33920951 DOI: 10.3390/cancers13081900 |
0.245 |
|
| 2016 |
Rader J, Sill M, Garcia F, Beumer J, Benbrook D, Zuna R, Spirtos N, Hamilton C, Lele S, Byron J, Alberts D, Trimble C. A stratified randomized double-blind phase II trial of celecoxib in the treatment of patients with cervical intraepithelial neoplasia: A Gynecologic Oncology Group (GOG 0207) study with translational biomarkers and drug level monitoring Gynecologic Oncology. 141: 21. DOI: 10.1016/J.Ygyno.2016.04.079 |
0.245 |
|
| 2020 |
Mahjabeen S, Hatipoglu MK, Kosanke SD, Garcia-Contreras D, Benbrook DM, Garcia-Contreras L. Vaginal Suppositories Containing Sheta2 To Treat Cervical Dysplasia: Pharmacokinetics Of Daily Doses And Preliminary Safety Profile. Journal of Pharmaceutical Sciences. PMID 32113976 DOI: 10.1016/J.Xphs.2020.02.016 |
0.245 |
|
| 2002 |
Kamelle S, Sienko A, Benbrook DM. Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertility and Sterility. 78: 596-602. PMID 12215339 DOI: 10.1016/S0015-0282(02)03302-2 |
0.241 |
|
| 2007 |
McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecologic Oncology. 106: 596-603. PMID 17597196 DOI: 10.1016/J.Ygyno.2007.05.013 |
0.241 |
|
| 1988 |
Pfahl M, Benbrook D. Nucleotide sequence of cDNA encoding a novel human thyroid hormone receptor. Nucleic Acids Research. 15: 9613. PMID 3684612 DOI: 10.1093/Nar/15.22.9613 |
0.24 |
|
| 2011 |
Nammalwar B, Bunce RA, Benbrook DM, Lu T, Li HF, Chen YD, Berlin KD. Synthesis of N-[3,4-dihydro-4-(acetoxymethyl)-2,2,4-trimethyl-2H-1- benzothiopyran-6-yl]-N'-(4-nitrophenyl)thiourea and N-[3,4-dihydro-4- (hydroxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-N'-(4-nitrophenyl) thiourea, a Major Metabolite of N-(3,4-dihydro-2,2,4,4-tetramethyl-2H-1- benzothiopyran-6-YL)-N'-(4-nitrophenyl)thiourea Phosphorus, Sulfur and Silicon and the Related Elements. 186: 189-204. DOI: 10.1080/10426507.2010.534521 |
0.24 |
|
| 1997 |
Miller AM, Sahl WJ, Brown SA, Young SK, Quinlan CM, Patel PR, Benbrook DM, Naylor MR. The role of human papillomavirus in the development of pyogenic granulomas International Journal of Dermatology. 36: 673-676. PMID 9352408 DOI: 10.1046/J.1365-4362.1997.00283.X |
0.238 |
|
| 2012 |
McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecologic Oncology. 127: 356-61. PMID 22796461 DOI: 10.1016/J.Ygyno.2012.07.095 |
0.237 |
|
| 2011 |
Dozmorov IM, Jarvis J, Saban R, Benbrook DM, Wakeland E, Aksentijevich I, Ryan J, Chiorazzi N, Guthridge JM, Drewe E, Tighe PJ, Centola M, Lefkovits I. Internal standard-based analysis of microarray data2--analysis of functional associations between HVE-genes. Nucleic Acids Research. 39: 7881-99. PMID 21715372 DOI: 10.1093/Nar/Gkr503 |
0.236 |
|
| 2011 |
Zheng J, Benbrook DM, Yu H, Ding WQ. Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Research. 31: 2739-47. PMID 21868515 |
0.236 |
|
| 2023 |
Sharma A, Liu X, Chandra V, Rai R, Benbrook DM, Woo S. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. The Aaps Journal. 26: 5. PMID 38087107 DOI: 10.1208/s12248-023-00874-7 |
0.233 |
|
| 2015 |
Benbrook DM. Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes Into Drugs, 2nd Edition Clinical Infectious Diseases. 60: 331-332. DOI: 10.1093/Cid/Ciu792 |
0.231 |
|
| 1987 |
Pfahl M, Benbrook D. Identification of cDNA clones coding for novel thyroid hormone receptors Journal of Steroid Biochemistry. 28: 13. DOI: 10.1016/0022-4731(87)91134-4 |
0.23 |
|
| 1997 |
Benbrook DM, Shen-Gunther J, Nuñez ER, Dynlacht JR. Differential retinoic acid radiosensitization of cervical carcinoma cell lines Clinical Cancer Research. 3: 939-945. PMID 9815769 |
0.206 |
|
| 2012 |
Nugent E, Long A, Mathews C, Bishop E, Moxley K, Benbrook D, Wild R, McMeekin D. Biomarkers associated with metabolic syndrome, endometrioid adenocarcinoma (EC) of the uterus, and disease prognosis. Gynecologic Oncology. 127: S7-8. PMID 24989593 DOI: 10.1016/J.Ygyno.2012.07.021 |
0.199 |
|
| 2023 |
Rai R, Conrad R, Benbrook DM. Dataset on mucin 1 and 4 proteins and SialyT and T antigens staining patterns in cervical cancer primary tumors and metastatic lymph nodes. Data in Brief. 48: 109243. PMID 37383750 DOI: 10.1016/j.dib.2023.109243 |
0.195 |
|
| 2021 |
Cybula M, Wang L, Wang L, Drumond-Bock AL, Moxley KM, Benbrook DM, Gunderson-Jackson C, Ruiz-Echevarria MJ, Bhattacharya R, Mukherjee P, Bieniasz M. Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. Cancers. 13. PMID 34944908 DOI: 10.3390/cancers13246288 |
0.191 |
|
| 1998 |
Madler MM, Klucik J, Soell PS, Brown CW, Liu S, Berlin KD, Benbrook DM, Birckbichler PJ, Nelson EC. Lithium hypochlorite-clorox as a novel oxidative mixture for methyl ketones and methyl carbinols Organic Preparations and Procedures International. 30: 230-234. DOI: 10.1080/00304949809355286 |
0.184 |
|
| 2016 |
Chandra V, Kim JJ, Benbrook DM, Dwivedi A, Rai R. Therapeutic options for management of endometrial hyperplasia Journal of Gynecologic Oncology. 27. DOI: 10.3802/jgo.2016.27.e8 |
0.184 |
|
| 2014 |
Okon I, Slaughter K, Scott B, McMeekin D, Benbrook D. Expression profiles of LKB1/AMPK in endometrial cancer specimens as a potential biomarker for targeted metabolic drug therapy Gynecologic Oncology. 133: 123. DOI: 10.1016/j.ygyno.2014.03.322 |
0.183 |
|
| 2022 |
Benbrook DM, Hocker JRS, Moxley KM, Hanas JS. Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. International Journal of Molecular Sciences. 23. PMID 35328698 DOI: 10.3390/ijms23063277 |
0.175 |
|
| 2020 |
Leslie KK, Thiel KW, Benbrook DM, Mutch D. The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. Cancers. 12. PMID 33120871 DOI: 10.3390/cancers12113135 |
0.172 |
|
| 2018 |
Carlson B, Jones K, Carlson J, Craft M, Benbrook D, Coleman-Jackson R, Hershey L. Cerebral Oxygenation And Sleep Disordered Breathing In Adults With Mild Cognitive Impairment. Innovation in Aging. 2: 136-137. DOI: 10.1093/Geroni/Igy023.498 |
0.166 |
|
| 1996 |
Qim X, Benbrook DM, Berlin KD, Cushman IC, Madlar MM, Patrick SD, Simms MD, Nelron FC. Comparative effects of a diaryl heteroarotinoid and all-muu-retinoic acid on induction of differentiation Faseb Journal. 10: A759. |
0.162 |
|
| 2017 |
Sharma A, Thavathiru E, Benbrook DM, Woo S. Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study. Journal of Pharmaceutical Technology & Drug Research. 6. PMID 29708233 DOI: 10.7243/2050-120X-6-2 |
0.161 |
|
| 2021 |
Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, ... ... Benbrook DM, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Autophagy. 1-382. PMID 33634751 DOI: 10.1080/15548627.2020.1797280 |
0.153 |
|
| 2022 |
Ade CJ, Dockery L, Walter AC, Benbrook DM, Vesely SK, Hammond ST, Moore KN, Holman LL. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutrition and Cancer. 1-8. PMID 36495155 DOI: 10.1080/01635581.2022.2152060 |
0.143 |
|
| 2023 |
Benbrook DM, Deng W, Gold MA, Rai R, Conrad R, van der Wel H, Husain S, Moore K, Spirtos N, Jackson AL, Zakhour M, Mathews CA, West CM. Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study. Gynecologic Oncology. 171: 67-75. PMID 36827840 DOI: 10.1016/j.ygyno.2023.02.001 |
0.142 |
|
| 1990 |
Benbrook DM, Jones NC. Heterodimer formation between CREB and Jun proteins Oncogene. 5: 295-302. PMID 2138276 |
0.136 |
|
| 2018 |
Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. PMID 29804200 DOI: 10.1007/s11357-018-0025-z |
0.121 |
|
| 1986 |
Benbrook DM, Miller RV. Effects of norfloxacin on DNA metabolism in Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 29: 1-6. PMID 3015000 |
0.109 |
|
| 2004 |
Alberts DS, Barakat RR, Daly M, Method MW, Benbrook DM, Boggess JF, Brewer MA, Brinton LA, Castle PE, Davanipour Z, Garcia FAR, Hanly MG, Hess LM, Hines JF, Kelaghan J, et al. Prevention of Gynecologic Malignancies Gynecologic Cancer: Controversies in Management. 883-919. DOI: 10.1016/B978-0-443-07142-3.50070-1 |
0.106 |
|
| 1998 |
Simms-Kelley MD, Subramanian S, Spruce LW, Madler MM, Patrick SD, Grummer R, Lemire TD, Benbrook DM, Birckbichler PJ, Berlin KD, Nelson EC. Growth promoting activity of heteroarotinoids in vitamin A-deficient rats Faseb Journal. 12: A840. |
0.105 |
|
| 2011 |
Benbrook DM. Dr Benbrook Biologics: Targets and Therapy. 5. |
0.029 |
|
| Hide low-probability matches. |